

Gilead Sciences Beat Expectations
Gilead Sciences (GILD) reported earnings of $1.81 per share on revenue of $6.67 billion for the first quarter ended March 2025. The consensus earnings estimate was $1.82 per share on revenue of $6.79 billion. The Earnings Whisper number was $1.79 per share. The company beat expectations by 1.12% while revenue fell 0.28% compared to the same quarter a year ago.
The company said it continues to expect 2025 earnings of $7.70 to $8.10 per share on revenue of $28.20 billion to $28.60 billion. The current consensus earnings estimate is $7.92 per share on revenue of $28.66 billion for the year ending December 31, 2025.
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.
-